ArticleMedicine2026
Systemic inflammation response index: A good predictor of 30-day all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the association between the systemic inflammation response index (SIRI) and the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) by retrospectively analyzing clinical data derived from the Medical Information Mart for Intensive Care-III (MIMIC-III) database. A total of 426 AECOPD patients were enrolled in this study, among whom 113 died during the 30-day follow-up period, resulting in a mortality rate of 26.6%. Compared with the survival group, patients in the deceased group had higher levels of SIRI (4.19 [2.19-7.68) versus 6.25 (3.09-15.57) ×109/L, P<.001]. X-tile software was utilized to determine the optimal SIRI cutoff value of 10.56 × 10-9/L for predicting 30-day all-cause mortality. Patients were stratified into 2 groups based on this cutoff value: a low SIRI group (<10.56 × 109/L) and a high SIRI group (≥10.56 × 109/L). Baseline characteristic comparisons demonstrated that patients in the high-SIRI group presented significantly higher 30-day, 90-day, 1-year, and in-hospital mortality than those in the low-SIRI group (all P < .05). After adjustment for potential confounders, the Cox proportional-hazards regression model identified elevated SIRI as an independent risk factor for 30-day all-cause mortality (HR = 1.743, 95%CI: 1.169-2.598, P = .006), and subgroup analyses confirmed the robustness of this correlation. Additionally, ROC curves showed that the area under the curve (AUC) for SIRI was greater than that for white blood cells and neutrophils (AUC 0.612 vs 0.584; 0.612 vs 0.557), but slightly smaller than that for sequential organ failure assessment (AUC 0.612 vs 0.619). Collectively, our findings indicate that SIRI represents a promising novel inflammatory biomarker for predicting 30-day all-cause mortality among patients with AECOPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.